NO20022455L - Sulfonyloksazolaminer og deres anvendelse som 5-HT6- reseptorligander - Google Patents

Sulfonyloksazolaminer og deres anvendelse som 5-HT6- reseptorligander

Info

Publication number
NO20022455L
NO20022455L NO20022455A NO20022455A NO20022455L NO 20022455 L NO20022455 L NO 20022455L NO 20022455 A NO20022455 A NO 20022455A NO 20022455 A NO20022455 A NO 20022455A NO 20022455 L NO20022455 L NO 20022455L
Authority
NO
Norway
Prior art keywords
sulfonyloxazolamines
nitrogen
oxygen
compounds
independently
Prior art date
Application number
NO20022455A
Other languages
English (en)
Other versions
NO20022455D0 (no
Inventor
Rolf Gericke
Henning Boettcher
Michael Gassen
Hartmut Greiner
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20022455L publication Critical patent/NO20022455L/no
Publication of NO20022455D0 publication Critical patent/NO20022455D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Oppfinnelsen vedrører forbindelser med den generelle formel (I) O) hvor R! og R2 er uavhengig av hverandre H, -Rs, C3- Cg-sykloalkyl, -(CH2)n-R7, -(CH2)n-O-R6, -(CH2)n- NH2, -(CH2)n-NHR6) -(CH2)-N(R6)2) C2-C6-alkenyl eller danner eventuelt til sammen en énkjernet, mettet heteroring med ett eller to nitrogen-, oksygen- og/eller svovelatomer; R3 og R4 er uavhengig av hverandre H, -Rs, -CF3, -NO2, -Hal, -OH, -O-Rs, -NH2, -NH-Rs eller -N(R6)2; R5 er en mettet eller umettet heteroring med 5 eller 6 medlemmer, med ett eller to nitrogen-, oksygen- og/eller svovelatomer, som eventuelt er mono- eller disubstituert med -R^, -CF3, -NO2, -Hal, -OH, -O-Rs, -NH2, -NH-R6 eller -N(R6)2; R,, er C,-C6- alkyl; R-, er sammen med R3 og/eller R4 fenyl som er substituert; og n er 0-2; samt deres fysiologisk akseptable salter eller solvater. Oppfinnelsen vedrører også anvendelsen av forbindelsene med den generelle formel (I) som medikamenter.
NO20022455A 1999-11-25 2002-05-24 Sulfonyloksazolaminer og deres anvendelse som 5-HT6- reseptorligander NO20022455D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19956791A DE19956791A1 (de) 1999-11-25 1999-11-25 Neue Sulfonyloxazolamine
PCT/EP2000/011734 WO2001038316A2 (de) 1999-11-25 2000-11-24 Sulfonyloxazolamine und deren verwendung als 5-ht6 rezeptorliganden

Publications (2)

Publication Number Publication Date
NO20022455L true NO20022455L (no) 2002-05-24
NO20022455D0 NO20022455D0 (no) 2002-05-24

Family

ID=7930321

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022455A NO20022455D0 (no) 1999-11-25 2002-05-24 Sulfonyloksazolaminer og deres anvendelse som 5-HT6- reseptorligander

Country Status (18)

Country Link
US (1) US6737426B1 (no)
EP (1) EP1233963A2 (no)
JP (1) JP2003514902A (no)
KR (1) KR20020058020A (no)
CN (1) CN1423649A (no)
AR (1) AR026589A1 (no)
AU (1) AU3004201A (no)
BR (1) BR0015814A (no)
CA (1) CA2389679A1 (no)
CZ (1) CZ20021687A3 (no)
DE (1) DE19956791A1 (no)
HU (1) HUP0204149A3 (no)
MX (1) MXPA02005092A (no)
NO (1) NO20022455D0 (no)
PL (1) PL355152A1 (no)
SK (1) SK6942002A3 (no)
WO (1) WO2001038316A2 (no)
ZA (1) ZA200203365B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10129940A1 (de) * 2001-06-13 2002-12-19 Merck Patent Gmbh Sulfonyloxazolamine als therapeutische Wirkstoffe
WO2008061248A2 (en) * 2006-11-16 2008-05-22 The Regents Of The University Of California Phenylsulfoxyoxazole compound inhibitors of urea transporters
DE602007012683D1 (de) * 2007-07-19 2011-04-07 Esteve Labor Dr Substituierte Tetrahydro-Chinolinsulfonamidverbindungen, ihre Herstellung und ihre Verwendung als Medikamente
RU2443697C1 (ru) * 2010-12-21 2012-02-27 Александр Васильевич Иващенко Замещенные метил-амины, антагонисты серотониновых 5-ht6 рецепторов, способы получения и применения
KR102533605B1 (ko) * 2018-01-10 2023-05-17 주식회사 라이조테크 신규한 페닐설포닐 옥사졸 유도체 및 이의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0930302B1 (en) 1998-01-16 2003-04-02 F.Hoffmann-La Roche Ag Benzosulfone derivatives
US6194410B1 (en) * 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
DE19858593A1 (de) 1998-12-18 2000-06-21 Merck Patent Gmbh Sulfonyloxazolamine als therapeutische Wirkstoffe

Also Published As

Publication number Publication date
ZA200203365B (en) 2003-10-07
CZ20021687A3 (cs) 2002-08-14
US6737426B1 (en) 2004-05-18
DE19956791A1 (de) 2001-05-31
BR0015814A (pt) 2002-07-23
SK6942002A3 (en) 2002-12-03
PL355152A1 (en) 2004-04-05
HUP0204149A3 (en) 2005-04-28
NO20022455D0 (no) 2002-05-24
EP1233963A2 (de) 2002-08-28
CN1423649A (zh) 2003-06-11
CA2389679A1 (en) 2001-05-31
MXPA02005092A (es) 2002-11-07
WO2001038316A2 (de) 2001-05-31
WO2001038316A3 (de) 2001-10-18
AR026589A1 (es) 2003-02-19
KR20020058020A (ko) 2002-07-12
JP2003514902A (ja) 2003-04-22
HUP0204149A2 (hu) 2003-04-28
AU3004201A (en) 2001-06-04

Similar Documents

Publication Publication Date Title
AR042691A1 (es) Agonistas inversos del receptor cb1 procedimientos de obtencion y composiciones farmaceuticas.
PE20210040A1 (es) Moduladores de la via de estres integrada
AR035825A1 (es) Ciclobuten-1,2-dionas 3,4-di-sustituidas y sus sales como ligandos del receptor de cxc-quimiocina, composiciones farmaceuticas y el uso de las mismas para la fabricacion de un medicamento
AR063101A1 (es) Derivados de pirazina-2-carboxiamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento o profilaxis de enfermedades asociadas con la modulacion de receptores del cb2.
NO20061076L (no) (Tio)karbamoylsykloheksanderivater som D3/D2 -reseptorantagonister
CO5251381A1 (es) Derivados de adamantano, un proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20060363A1 (es) DERIVADOS DE TETRAAZABENZO[e]AZULENO Y SUS ANALOGOS
PE20030269A1 (es) Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas
AR055878A1 (es) Derivados de ciclopropanocarboxamida
PE20030039A1 (es) Derivados de indol con afinidad por el receptor 5-ht6
AR048641A1 (es) Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame
AR024969A1 (es) Derivados de 8-fenil-6,9-dihidro-[1,2,4]triazol[3,4-i]purin-5-ona
DK526188D0 (da) Benzimidazolin-2-oxo-1-carboxylsyrederivater til anvendelse som 5-ht receptorantagonister i farmaceutiske praeparater
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
AR038703A1 (es) Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
AR045931A1 (es) Derivados de piperazina
NO20101069L (no) Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva
AR040333A1 (es) Uso de derivados de ciclotiocarbamatos en el tratamiento de condiciones relacionadas con hormonas
AR018917A1 (es) Compuestos derivados de adenosina que son agonistas en el receptor adenosina a1, proceso para su preparacion, composiciones farmaceuticas que los contienen.
HUP0004436A2 (hu) FP agonistákként alkalmazható aromás C16-C20-szubsztituált tetrahidroprosztaglandinok
ES2092651T3 (es) Derivados heterociclicos diazotados n-sustituidos por un grupo bifenilmetilo, su preparacion, las composiciones farmaceuticas que los contienen.
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
DE60033964D1 (de) Phenoxypropanolamin-derivate, ihre herstellung und therapeutische verwendung
PE20030761A1 (es) Derivados del 7-amino-benzotiazol

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application